The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon

AUTOR(ES)

Sousa, Taís Nóbrega de, Kano, Flora Satiko, Brito, Cristiana Ferreira Alves de, Carvalho, Luzia Helena

FONTE

Mem. Inst. Oswaldo Cruz

DATA DE PUBLICAÇÃO

2014-08

RESUMO

Plasmodium vivax infects human erythrocytes through a major pathway that requires interaction between an apical parasite protein, the Duffy binding protein (PvDBP) and its receptor on reticulocytes, the Duffy antigen/receptor for chemokines (DARC). The importance of the interaction between PvDBP (region II, DBPII) and DARC to P. vivax infection has motivated our malaria research group at Oswaldo Cruz Foundation (state of Minas Gerais, Brazil) to conduct a number of immunoepidemiological studies to characterise the naturally acquired immunity to PvDBP in populations living in the Amazon rainforest. In this review, we provide an update on the immunology and molecular epidemiology of PvDBP in the Brazilian Amazon - an area of markedly unstable malaria transmission - and compare it with data from other parts of Latin America, as well as Asia and Oceania.

Documentos Relacionados

• Naturally Acquired and Vaccine-Elicited Antibodies Block Erythrocyte Cytoadherence of the Plasmodium vivax Duffy Binding Protein
• Epitope-Specific Humoral Immunity to Plasmodium vivax Duffy Binding Protein
• Genetic variability and natural selection at the ligand domain of the Duffy binding protein in Brazilian Plasmodium vivax populations
• Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein.
• Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein.